- Report
- February 2024
- 113 Pages
Global
From €4594EUR$4,750USD£3,937GBP
- Report
- May 2019
- 835 Pages
Global
From €8220EUR$8,500USD£7,045GBP
- Report
- August 2023
Japan, United States, ... Japan, United States, Europe
From €1451EUR$1,500USD£1,243GBP
- Report
- April 2022
Japan, United States, ... Japan, United States, Europe, Global
From €2659EUR$2,750USD£2,279GBP
- Report
- December 2021
Global
From €4690EUR$4,850USD£4,020GBP
- Report
- February 2020
- 235 Pages
Japan, United States, ... Japan, United States, Europe, Global
From €4352EUR$4,500USD£3,730GBP
- Report
- July 2019
- 835 Pages
Global
From €8220EUR$8,500USD£7,045GBP
From €919EUR$950USD£787GBP
The Rubella Test is a type of infectious disease testing used to detect the presence of rubella antibodies in a person's blood. It is used to diagnose rubella infection, as well as to determine if a person has been vaccinated against the virus. The test is typically performed by a healthcare provider, such as a doctor or nurse, and results are usually available within a few days.
The Rubella Test market is a subset of the larger infectious disease testing market, which is estimated to be worth billions of dollars. The market is driven by the need to diagnose and treat infectious diseases, as well as the increasing prevalence of rubella in certain parts of the world.
Some companies in the Rubella Test market include Abbott Laboratories, Becton Dickinson, Bio-Rad Laboratories, Cepheid, and Roche Diagnostics. Show Less Read more